18/06/2026
uniQure previously announced positive results from its new gene therapy treatment for Huntington's disease. The Phase I/II trial showed that AMT-130 slowed disease progression by 75% over 36 months.
In April, uniQure announced that it had held a pre-submission meeting with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and plans to submit a Marketing Authorisation Application (MAA) for AMT-130 later in 2026.
uniQure has now announced further progress with the US Food and Drug Administration (FDA). The FDA had previously said it would not accept the trial data. It has now confirmed that the data can be used as the main evidence in a Biologics License Application (BLA) for accelerated approval of AMT-130 as a treatment for Huntington's disease.
Cath Stanley BEM, Chief Executive of the Huntington’s Disease Association, said:
“Any news that the drug is being seriously considered for licensing is progress. However, as always, there has to be some caution. This process will take time. However, it seems both the UK and USA are open to the next stages. As a charity, we will continue to advocate for anyone affected by Huntington’s disease and will do all we can to support the community in gaining access to any potential treatments.”
You can read more about the update and timeline here:
uniQure previously announced positive results of a new gene therapy treatment for Huntington's disease. The phase I/II study has shown that the treatment - AMT-130 - causes a statistically significant slowing (75%) of disease progression when measured at 36 months.